Replies to post #2371 on Immunotech Laboratories Inc (IMMB)

[NanoEE]

This has to be IMMB.

https://rosettalifecarebg.com/

At Mode 1, on the Rosetta web site, they have the same verbiage as in IMMB's website.

https://www.immunotechlaboratoriesbg.com/f-i-immunomodulator

When you get to the ITV Survey, and they start talking about the GP41 and GP120.

https://backend.otcmarkets.com/otcapi/company/financial-report/275843/content

On January 15, 2018, the merger agreement with Immunotech Laboratories, Inc. was terminated except for Section 1.03(d)(i) which relates to the appointment of Harry Zhabilov as Chairman and CEO of ECPO which remained in effect.

Page F-33
March 22, 2021, The Company has entered negotiations with Pro Wave Ad Product ("PWA"), a Bulgarian Company, to supply the raw material for PWA's Contract in India for the production of a spray modulating the immune system under U.S. Patent No. 8,309,072 owned by Zhabilov Trust.

March 22, 2021, As a result of the necessity to perform Clinical trials under the EMA guidelines, the agreements with IMMB BG, which were in default, have been cancelled and superseded by the new agreements with IMBL and PAW. The ITV-1 treatment that successfully completed Phase 3 clinical trials on August 7, 2014, with the Final Report being issued in November of 2016 by Assoc. Prof. Ivaylo Elenkov, MD, Chief researcher at the Specialized Hospital for Active Treatment of Infectious and Parasite Diseases. This report and the associated clinical trials were conducted under Bulgarian Drug Administration(BDA) guidelines. With Bulgaria joining the EMA in April of 2019, the BDA can no longer issue permits for mass use for the HIV/AIDS virus. Under the Company's new business arrangement with International Medical Partners, Ltd. (IMBL), new clinical trials are being planned and scheduled with Clinical Design, a Clinical Research Organization (CRO) in Bulgaria. The Company is finalizing negotiations with a Contract Manufacturer, also located in Bulgaria, for the production of the ITV-1 Immunotherapy treatment. The new clinical trials for the Patented and licensed ITV-1 treatment under the EMA guidelines will be submitted upon completion. When the EMA permit for mass use is issued, the Company plans to pursue Federal Drug Administration (FDA) approval under the Mutual Recognition Agreement between the FDA and EMA.

Spray Modulating, which the website touts.

HERE IT IS:
PRO Wave, Valentine is connectedBAM!!!

https://papagal.bg/person/48085159552C9A812EF81EA2C8D0334845377DAD54BE66B16CEB7302F4BDA0A3